Kempner, W.: Treatment of hypertensive vascular disease with rice diet. Amer J Med4: 545, 1948.
2.
Dustan, H.P., Cumming, G.R., Corcoran, A.C., et al: A mechanism of chlorthiazide enhanced effectiveness of antihypertensive ganglioplegic drugs. Circulation19: 360, 1959.
3.
Frohlich, E.D. , Schnaper, H.W., Wilson, I.M., et al: Hemodynamic alterations in hypertensive patients due to chlorthiazide. N Engl J Med262: 1261, 1960.
4.
Wilson, I.M., and Freis, E.D.: Relationship between plasma and extracellular effect of chlorthiazide. Circulation20: 1028, 1959.
5.
Davidov, M.E. , Gavrilovich, L., Mroczek, W.J., et al: Relation of extracellular fluid volume to arterial pressure during drug-induced saluresis. Circulation40: 349-355, 1969.
6.
Finnerty, F.A. Jr., Kakaviatos, N., Tuckman, J., et al: Clinical evaluation of diazoxide: a new treatment for acute hypertension. Circulation28: 203-208, 1963.
7.
Greene, A.M., Boltax, A.J., Scherr, E.S., et al: Mechanisms by which chlorthiazide potentiates the vasodepressor effect of a ganglion blocking agent (trimethaphan). Am J Med36: 87, 1964.
Lohmoller, G. , Lohmoller, R., Pfeffer, M.A., et al: Mechanism of immediate hemodynamic effects of chlorthiazide. Am Heart J89: 487-492, 1975.
10.
Fine, L.G., Weber, H., Bourgoignie, J., et al: On the end-organ responsiveness of the rat kidney to the natriuretic factor from urine of patients with chronic uremia. (Abstract) presented to The American Society of Nephrology 6th Annual Meeting , Washington, D.C., November 19-20, 1973.
11.
Meriwether, W.D., Mangi, R.J., and Serpick A.A.: Deafness following standard intravenous dose of ethecrynic acid. JAMA216: 795-798, 1971.
12.
Slone, D., Jick, H., Lewis, G.P., et al: Intravenously given ethacrynic acid and gastrointestinal bleeding . JAMA209: 1668-1672, 1969 . '
13.
Mroczek, W.J. , Davidov, M.E., Horoschak, A., et al: Canrenoate in normal man. Clin Pharmacol Ther16: 336-342, 1974
14.
Freis, E.D.: Introduction to the nature and management of hypertension. Robert J. Brady Company, 1974, 107.
15.
Crane, M.G. and Harris, J.J.: The effect of spironolactone in hypertensive patients. Am J Med Sci260: 311-330, 1970.
16.
Carey, R.M. , Douglas, J.G., Schweikert, R., et al: The syndrome of essential hypertension and suppressed plasma renin activity. Arch Intern Med130: 849-854, 1972.
17.
Mroczek, W.J. , Leibel, B.A. and Finnerty, F.A., Jr.: Comparison of clonidine and methyldopa in hypertensive patients receiving a diuretic. Am J Cardiol29: 712-717, 1972.
18.
Mroczek, W.J. , Davidov, M.E. and Finnerty, F.A. Jr.: Prolonged treatment with clonidine: comparative antihypertensive effects alone and with a diuretic agent. Am J Cardiol30. 536-541, 1972.
19.
Finnerty, F.A. , Jr., Davidov, M.E., Mroczek, W.J., et al: Influence of extracellular fluid volume on response to antihypertensive drugs. Hypertension18: I-71-182, 1970.
20.
Mroczek, W.J. , Davidov, M.E. and Finnerty, F.A., Jr.: Large dose furosemide therapy for hypertension. Am J Cardiol33: 546-549, 1974.
21.
Dustan, H.P. , Tarazi, R.C. and Bravo, E.L.: Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Eng J Med286: 861-866, 1972.
22.
Mroczek, W.J. , Davidov, M.E., Gavrilovich, L., et al: The value of aggressive therapy in the hypertensive patient with azotemia. Circulation40: 893-904, 1969.
23.
Mroczek, W.J. , Moir, D., Davidov, M.E., et al: Sodium intake and furosemide administration in azotemic patients with severe hypertension. Presented to the twenty-fourth annual scientific session of the American College of Cardiology, Houston, Texas, February 10-13, 1975.